With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in ...
The latest HPRA inspection in February 2025 was highly successful-both QC licences were renewed, and viral vector manufacturing was added to the MIA (IMP) licence. This means the Shannon site can ...
Live Science on MSN22h
POLG diseases: Rare genetic conditions that starve cells of energy and afflicted the late Prince of LuxembourgPOLG-related diseases disrupt the function of the mitochondria, or "powerhouses" of the cell — starving them of energy.
A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and Louis Garza at Johns Hopkins University, has developed a compound that could ...
A mother has spoken about her "painful" experience over the potential end to her son's life-enhancing treatment for a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback